- Cellect Biotechnology Ltd (NASDAQ:APOP) has filed a registration statement with the SEC in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals Inc.
- See the SEC registration document here.
- In March, the companies entered into a reverse merger agreement.
- Quoin is a specialty pharmaceutical company focused on rare and orphan diseases.
- The transaction is expected to close in Q3 of 2021.
- The Company believes the progress of Quoin’s clinical programs and the secured investments of $25.5 million will benefit and maximize Cellect shareholders.
- After the deal completion, Cellect will be renamed Quoin Pharmaceuticals and will start trading under the ticker QNRX on NASDAQ.
- Price Action: APOP shares are up 34.6% at $4.40 during the premarket trading session on the last check Thursday.
ZoomInfo Reports Partnership With Beyond Codes To Provide Intelligence To India, East Asia, No Terms Disclosed
ZoomInfo (NASDAQ:ZI), a global leader in go-to-market intelligence solutions, today announced a partnership with Beyond Codes, Inc., a leading B2B demand generation company serving customers in India and globally. This